摘要
目的:探讨Kallikrein 10(KLK10)基因在不同前列腺组织中的表达情况。方法:采用荧光定量PCR方法检测3例正常前列腺组织、5例BPH组织、6例前列腺癌细胞株、35例前列腺癌组织中KLK10 mRNA的表达水平。结果:正常前列腺组织、良性前列腺增生组织、前列腺癌细胞株、前列腺癌组织KLK10 mRNA表达相对值分别为0.521、0.487、0.021、0.018,组间比较差异有统计学意义(P<0.01)。骨转移前列腺癌与未转移前列腺癌KLK10 mRNA表达相对值分别为0.003、0.023,两组比较差异有统计学意义(P<0.05)。结论:KLK10在前列腺癌组织中表达下调,在转移性前列腺癌中表达更低。KLK10表达下调可促进肿瘤的发生与进展。
Objective：To study the expression and significance of Kallikrein 10 （KLK10） mRNA in different tissues of the prostate. Methods.. Fluorescent quantitation PCR （FQ-PCR） method was used to detect the expression of KLK10 mRNA in normal prostate tissues （3 cases）, benign prostatic hyperplasia tissues （5 cases） , prostate cancer cell lines（ 6 cases） and prostate cancer （35 cases） tissues. Results：There were a obvious difference in the expressions of KLK10 mRNA between normal prostate tissues, benign prostatic hyperplasia tissues, prostate cancer cell lines and prostate cancer tissues （the relative values of mRNA expression were 0. 521, 0. 487, 0. 021, 0. 018 respectively, P〈0.01）. A obvious difference in the expressions of KLK10 mRNA was detected between prostate cancer tissues with bone metastasis and those without bone metastasis （the relative values of KLK10 mRNA expression were 0. 003, 0. 023, respectively, P〈0.05）. Conclusions： The expression of KLK10 is down regulation in prostate cancer tissues and less in metastatic prostate cancer. Down regulation of KLK10 expression contribute to the progress of prostate cancer.
出处
《临床泌尿外科杂志》
北大核心
2009年第5期387-388,392,共3页
Journal of Clinical Urology
基金
河南省基础与前沿技术研究计划项目(No:027300450100)
